Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 3/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101325 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1302931 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL8348104 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3050298 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL11753239 | 0.97 | TDP1 (0.71) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3761094 | 0.97 | TDP1 (0.71) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL6072946 | 0.97 | TDP1 (0.71) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL865783 | 0.90 | — | — | |
| SCHEMBL148513 | 0.90 | — | — | |
| SCHEMBL17101240 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 659 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317790-A | Pharmaceutical composition comprising p-borophenylalanine | 腾博龙公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2023111396-A1 | PHARMACEUTICAL COMPOSITION COMPRISING P-BORONOPHENYLALANINE | TENBORON OY (FI) | 2023-06-22 | — | — | WO | claimed |
| CN-108135897-B | Fused benzamides | 勃林格殷格翰国际有限公司 | 2021-07-27 | — | — | CN | claimed |
| CN-108473756-B | Polycarbonate resin composition, molded article, and carrier tape | 住化PC有限公司 | 2020-07-24 | — | — | CN | claimed |
| EP-3337483-B1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2019-10-09 | — | — | EP | claimed |
| EP-2974713-B1 | CERAMIDE-LIKE FUNCTION IMPARTING AGENT | KAO CORP (JP) | 2019-05-01 | — | — | EP | claimed |
| EP-3229591-B1 | SUGAR SURFACTANTS AND USE THEREOF IN AGROCHEMICAL COMPOSITIONS | CLARIANT INT LTD (CH) | 2018-10-03 | — | — | EP | claimed |
| EP-2872480-B1 | LIPASE-STABLE THICKENING AGENT | EVONIK DEGUSSA GMBH (DE) | 2018-09-26 | — | — | EP | claimed |
| US-20180186774-A1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2018-07-05 | — | — | US | claimed |
| EP-3337483-A1 | NOVEL ANNELATED BENZAMIDES | Boehringer Ingelheim International GmbH (DE) | 2018-06-27 | — | — | EP | claimed |
| EP-0998946-A1 | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-05-10 | — | — | EP | claimed |
| WO-2000009169-A1 | NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-02-24 | — | — | WO | claimed |
| EP-0767781-B1 | NOVEL QUATERNARY AMMONIUM DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF AS SURFACTANTS | SEPPIC SA (FR) | 1999-03-31 | — | — | EP | claimed |
| US-5756066-A | Iodine-containing peptides | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-05-26 | — | — | US | claimed |
| US-5674467-A | USED IN NMR DIAGNOSIS, RADIODIAGNOSIS OR RADIOTHERAPY | INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1997-10-07 | — | — | US | claimed |
| US-5508454-A | FOR BIOCOMPATIBLE CLEANING COMPOUNDS, CONDITIONERS, EMULSIFIERS OR FOAMS USEFUL IN COSMETIC OR DRUG DELIVERY MIXTURES | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES -SEPPIC (FR) | 1996-04-16 | — | — | US | claimed |
| US-5446027-A | Moisturizers improving skin roughness | KAO CORPORATION (JP) | 1995-08-29 | — | — | US | claimed |
| EP-0596450-A1 | Amide derivative and external skin care preparation containing the same | KAO CORPORATION (JP) | 1994-05-11 | — | — | EP | claimed |
| EP-0368763-B1 | 4-MERCAPTO BUTYRAMIDES N-MONO OR N,N-DISUBSTITUTED BY A MONO OR POLYHYDROXYALKYL RADICAL, AND THEIR USE AS REDUCING AGENTS IN THE PROCESS OF PERMANENT DEFORMATION OF THE HAIR | L'OREAL (FR) | 1992-10-14 | — | — | EP | claimed |
| WO-1982002889-A1 | AMMONIUM SALTS OF A SUBSTITUTED CARBONIC ACID,PREPARATION METHOD THEREOF,UTILIZATION AND MEDICINAL PREPARATIONS CONTAINING THEM | CIBA GEIGY AG (CH) | 1982-09-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186774-A1 | NOVEL ANNELATED BENZAMIDES | HDAC10, HDAC11, H1-0 | LMNA 3647/4885L3MBTL1 2738/4885TDP1 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.